Avelumab Flat Dose Regimen: Justification For Use In Advanced Renal Cell Carcinoma (Arcc)

John B. A. G. Haanen,Joanna C. Masters,Bo Huang,Toni K. Choueiri,Robert J. Motzer,Akash Khandelwal,Haiqing (Isaac) Dai,Alessandra di Pietro,Satjit Brar,Brian I. Rini,Laurence Albiges,James M. G. Larkin

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 0|浏览37

暂无评分

摘要

32Background: Avelumab, an anti–PD-L1 monoclonal antibody, was recently approved for the treatment of aRCC in combination with axitinib and was previously indicated for the treatment of metastatic ...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要